Caprico Biotechnologies, Inc., a Chinese biotechnology company, has entered into a comprehensive partnership with Mindray Medical International Limited, a fellow Chinese firm, to collaborate on research and development, manufacturing, and marketing in the field of flow testing. The agreement encompasses a wide range of activities, although financial specifics have not been disclosed.
Caprico Bio, with over a decade of experience in the flow antibody sector, has developed a robust set of core competencies. These include the research and development of hybridoma cell lines, purification and preparation of flow antibodies, coupling with fluorescent dyes, and quality control in the production of flow antibody reagents. The partnership with Mindray Medical is expected to leverage these capabilities to strengthen their position in the flow testing market. – Flcube.com
